Reports
Reports
Sale
The global peripheral neuropathy treatment market reached a value of about USD 764.27 million in 2023 and is expected to grow at a CAGR of 3.7% during the forecast period of 2024-2032. The market is expected to reach USD 1,059.88 million by 2032.
Peripheral Neuropathy Treatment Market Size
Peripheral Neuropathy Treatment Market Growth
Peripheral Neuropathy Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Peripheral Neuropathy Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Peripheral Neuropathy Treatment Market
6.1 Global Peripheral Neuropathy Treatment Market Overview
6.2 Global Peripheral Neuropathy Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Peripheral Neuropathy Treatment Market Historical Value (2017-2023)
6.2.1.2 Global Peripheral Neuropathy Treatment Market Forecast Value (2024-2032)
6.3 Global Peripheral Neuropathy Treatment Market by Type
6.3.1 Market Overview
6.3.1.1 Diabetic Peripheral Neuropathy
6.3.1.2 Chemotherapy-Induced Peripheral Neuropathy
6.3.1.3 Idiopathic Peripheral Neuropathy
6.3.1.4 HIV/AIDS Associated Peripheral Neuropathy
6.4 Global Peripheral Neuropathy Treatment Market by Therapeutics Method
6.4.1 Market Overview
6.4.1.1 Pharmacological Therapies
6.4.1.1.1 Pain Relievers
6.4.1.1.2 Anti-Seizure Medications
6.4.1.1.3 Anti-Depressants
6.4.1.2 Non-Pharmacological Therapies
6.4.1.2.1 Transcutaneous Electrical Nerve Stimulation
6.4.1.2.2 Plasma Exchange
6.4.1.2.3 Others
6.4.1.3 Others
6.5 Global Peripheral Neuropathy Treatment Market by End User
6.5.1 Market Overview
6.5.1.1 Hospitals And Clinics
6.5.1.2 Retail Pharmacy
6.5.1.3 Online Pharmacy
6.6 Global Peripheral Neuropathy Treatment Market by Treatment Channel
6.6.1 Public
6.6.2 Private
6.7 Global Peripheral Neuropathy Treatment Market by Region
6.7.1 Market Overview
6.7.1.1 North America
6.7.1.1.1 Historical Trend (2017-2023)
6.7.1.1.2 Forecast Trend (2024-2032)
6.7.1.2 Europe
6.7.1.2.1 Historical Trend (2017-2023)
6.7.1.2.2 Forecast Trend (2024-2032)
6.7.1.3 Asia Pacific
6.7.1.3.1 Historical Trend (2017-2023)
6.7.1.3.2 Forecast Trend (2024-2032)
6.7.1.4 Latin America
6.7.1.4.1 Historical Trend (2017-2023)
6.7.1.4.2 Forecast Trend (2024-2032)
6.7.1.5 Middle East and Africa
6.7.1.5.1 Historical Trend (2017-2023)
6.7.1.5.2 Forecast Trend (2024-2032)
7 North America Peripheral Neuropathy Treatment by Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2017-2023)
7.1.2 Forecast Trend (2024-2032)
7.2 Canada
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
8 Europe Peripheral Neuropathy Treatment by Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2017-2023)
8.1.2 Forecast Trend (2024-2032)
8.2 Germany
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3 France
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4 Italy
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
9 Asia Pacific Peripheral Neuropathy Treatment by Treatment Market
9.1 China
9.1.1 Historical Trend (2017-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Japan
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 India
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 ASEAN
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 Australia
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
10 Latin America Peripheral Neuropathy Treatment by Treatment Market
10.1 Brazil
10.1.1 Historical Trend (2017-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Argentina
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Mexico
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
11 Middle East and Africa Peripheral Neuropathy Treatment by Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2017-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 United Arab Emirates
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 Nigeria
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 South Africa
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
12 Current Scenario Evaluation and Regulatory Framework
12.1 Emerging Therapies and Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
12.2.1.1 Patent Status and Expiry
12.2.1.2 Timelines from Drug Development to Commercial Launch
12.2.1.3 New Drug Application
12.2.1.3.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
12.4.1.1 US FDA
12.4.1.2 EU EMA
12.4.1.3 INDIA CDSCO
12.4.1.4 JAPAN PMDA
12.4.1.5 Others
13 Challenges and Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop-Out Analysis
13.3 Awareness and Prevention Gaps
14 Global Peripheral Neuropathy Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Abbott Laboratories
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Bristol Myers Squibb Co
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Eli Lilly and Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Pfizer Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 GlaxoSmithKline Plc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Merck and Co. Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 F. Hoffmann-La Roche Ltd
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Cipla Ltd.
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Lupin Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Dr. Reddy’s Laboratories
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 RxFunction, Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Recommendations and Discussion
17 Global Peripheral Neuropathy Treatment Drugs Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of USD 764.27 million in 2023.
The market is likely to grow at a CAGR of 3.7% during the forecast period of 2024-2032.
The market is expected to reach a value of USD 1,059.88 million by 2032.
The rising prevalence of chronic diseases, such as diabetes, cancer, and hypothyroidism, increases the risk of peripheral neuropathy in chronic disease patients.
The major regional markets include North America, Europe, Latin America, Middle East and Africa, and Asia Pacific.
The major types include diabetic, chemotherapy-induced, idiopathic, and HIV/AIDS associated peripheral neuropathy.
The key players in the market include Abbott Laboratories, Bristol Myers Squibb Co, Novartis AG, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline Plc, Merck and Co. Inc., F. Hoffmann-La Roche Ltd, Cipla Ltd., Lupin Ltd, Dr. Reddy’s Laboratories, and RxFunction, Inc., among others.
High product costs, availability of alternative treatments, and stringent regulatory compliance and device recalls, are major factors impeding the market growth.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.